Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. - Wikidata - wikimedia - TriplyDB

Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial.

Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial.

http://www.wikidata.org/entity/Q44407642

about

Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients Cytomegalovirus infection in transplant recipients CMV: Prevention, Diagnosis and Therapy Human CMV-specific T-cell responses in kidney transplantation; toward changing current risk-stratification paradigm Direct and Indirect Effects of Cytomegalovirus-Induced γδ T Cells after Kidney Transplantation Cytomegalovirus post kidney transplantation: prophylaxis versus pre-emptive therapy?The Impact of Infection on Chronic Allograft Dysfunction and Allograft Survival After Solid Organ Transplantation Leflunomide: a drug with a potential beyond rheumatology Long-term impact of CMV infection on allografts and on patient survival in renal transplant patients with protocol biopsies.Identification and validation of urinary biomarkers for differential diagnosis and evaluation of therapeutic intervention in anti-neutrophil cytoplasmic antibody-associated vasculitis Impact of CMV infection on acute rejection and long-term renal allograft function: a systematic analysis in patients with protocol biopsies and indicated biopsies.Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection.A Systematic Review and Meta-analysis of Prophylactic versus Pre-emptive Strategies for Preventing Cytomegalovirus Infection in Renal Transplant Recipients.Impact of prophylactic versus preemptive valganciclovir on long-term renal allograft outcomes.Cytomegalovirus-responsive γδ T cells: novel effector cells in antibody-mediated kidney allograft microcirculation lesions.Post-transplant infections: An ounce of prevention.Incidence, risk factors, and outcomes of delayed-onset cytomegalovirus disease in a large, retrospective cohort of heart transplant recipients Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation.Use of leflunomide in renal transplant recipients with ganciclovir-resistant/refractory cytomegalovirus infection: a case series from the University of Chicago.The Microbiome, Systemic Immune Function, and Allotransplantation.Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation.Preformed frequencies of cytomegalovirus (CMV)-specific memory T and B cells identify protected CMV-sensitized individuals among seronegative kidney transplant recipients.Cytomegalovirus disease in African-American kidney transplant patients Two strategies for prevention of cytomegalovirus infections after liver transplantation.Pharmacoepidemiology of cytomegalovirus prophylaxis in a large retrospective cohort of kidney transplant recipients with Medicare Part D coverage.Ganciclovir prophylaxis improves late murine cytomegalovirus-induced renal allograft damage.Impaired direct priming of CD8 T cells by donor-derived cytomegalovirus following kidney transplantation.Cytomegalovirus infections in solid organ transplantation: a review.Defining the risks for cytomegalovirus infection and disease after solid organ transplantation.Strategies for managing cytomegalovirus in transplant recipients.Cytomegalovirus-associated renal allograft rejection: new challenges for antiviral preventive strategies.CMV in critically ill patients: pathogen or bystander?Valganciclovir to prevent or treat cytomegalovirus disease in organ transplantation.Update on cytomegalovirus infections of the gastrointestinal system in solid organ transplant recipients.TCR cross-reactivity and allorecognition: new insights into the immunogenetics of allorecognition.Advances in cytomegalovirus-preventive strategies in solid organ transplantation: defending pre-emptive therapy.Evaluation of clinical outcomes of prophylactic versus preemptive cytomegalovirus strategy in liver transplant recipients.The efficacy and cost-effectiveness of valacyclovir in cytomegalovirus prevention in solid organ transplantation.Expanding role of cytomegalovirus as a human pathogen.

P2860

Q24200697-1616B38B-1EBE-45E4-BFC2-33959344DAAD Q24200991-5B91BBD0-AA59-431B-B873-C531D7EEF1B9 Q26801802-5CC9626E-F425-4A2F-A3D8-9D47FE95AB19 Q26824869-B14219CD-E23D-4E55-B41F-38EBF1073755 Q26850340-5170F494-0929-4A68-9880-A2D6EF817126 Q26863724-15FB0D41-99AE-4442-9B3C-7C3B390ADE47 Q28082017-A15B4448-10F1-468A-9100-5B36A5B89E57 Q28085440-A0C1CA3E-A847-47B5-85FD-43AE1C7645E3 Q28294236-565BC068-4C3B-4DB8-A7A5-62D77C15C9BE Q30278721-E4EF9EE5-A295-4C7C-8A0F-F8046288F035 Q30434677-DAC1AB40-E506-42CA-A28B-AFEFAD610B42 Q30453768-2822FA35-EA57-4364-9962-E551FFD8A5B9 Q33561715-56F29935-8CF2-49E9-9030-D63D21D858B1 Q33871850-3AF44003-DCF7-4769-85CF-9E7521251736 Q34077023-9F89C5B0-2D3F-42C3-B5DE-009155DAF5B3 Q34427661-775F6032-0753-4FC0-A977-EAE3B3C7DBBE Q34435191-FE3C438D-CB0A-40C3-AFE1-DFC163C83876 Q34729119-DEA4CF04-0A3E-4611-AEBF-413B401AA541 Q35051236-EC0894F8-588B-4B4B-BB29-6D7DE3E0CEC6 Q35592509-F1619D25-2DF0-4429-B0EA-BADC2302618F Q35866187-13808D65-F333-4321-A421-F1C89DED6595 Q36200933-4AF712EC-0852-4D5F-B6C7-F48960F8BAF9 Q36293963-D56F7175-2A0D-4BC9-8D2D-C0882DF00CA1 Q36614140-975CA7C9-D1FC-4EDB-A1C8-F9A152770ABF Q36724385-F33A9DDB-6E11-4F83-BEE1-44158C7ABDB4 Q36759073-253CCC37-FCAE-4645-8C4A-3F46A32F8AD5 Q36979317-61B86E3D-AF0A-4E43-9700-4749F6C27AC0 Q37202784-D00481C1-358E-4C68-8FED-992D28F93C65 Q37359332-BFB55D81-E4C6-479A-ACDA-70725ABB0AF2 Q37680941-35D59998-3FE7-4424-BB1A-E82F9FD37E3A Q37773992-3CBD2A1A-B665-4768-A438-AA6E091994C2 Q37778827-2C9589C3-A3E1-4C73-A6F1-A7900A1E142C Q37798773-523819BF-2242-4D8E-8F1A-DB2AB17D6D29 Q37949634-3B57FA70-8568-4562-80A6-122D1FBC5F60 Q37962447-02AA9EB8-8E1A-4D9A-80F9-3E7ECB192031 Q37965366-A876865F-853E-44D6-AFA5-B62C11A68A6A Q37965695-9DD8F92F-591A-4473-88E7-4A473DFEE097 Q38099432-0E7A4793-B3A9-4150-8631-089E3EF0125F Q38254037-BDAA61A4-5D16-4D95-8A70-3DF3BBAE6016 Q38673038-1F8386D9-01CA-4562-8A00-7C3EF8575108

P2860

Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial.

http://www.wikidata.org/entity/Q44407642

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Improvement in long-term renal ...... f a randomized clinical trial.

@en

Improvement in long-term renal ...... f a randomized clinical trial.

@nl

type

label

Improvement in long-term renal ...... f a randomized clinical trial.

@en

Improvement in long-term renal ...... f a randomized clinical trial.

@nl

prefLabel

Improvement in long-term renal ...... f a randomized clinical trial.

@en

Improvement in long-term renal ...... f a randomized clinical trial.

@nl

P1433

Q44407642-CD81C471-0BA5-4648-AE30-E5D502110474

P1476

Q44407642-79C51D79-661A-48F0-B8AC-E8A62343B8FC

P2093

Q44407642-1ECAD40D-13AA-4844-9D50-677561F981B1

Q44407642-633FA1A7-FF54-4BB6-B10C-DA79189A8A21

Q44407642-7056DCB0-AAC2-4F83-B730-E76B2DBFEDCF

Q44407642-70D7958F-574E-486A-997F-8869817E4A3C

Q44407642-978CD5D1-C04F-483E-A87D-E1B98172F5E9

Q44407642-CDF77241-EB9C-4607-9561-38B13F02E395

P2860

Q44407642-00E1264E-33E0-4131-9D75-F9B0D0732E7C

Q44407642-0CEFB805-15E2-411A-8E00-28ABD1B6D064

Q44407642-12E3A0A8-1008-46B1-BDD1-307901B8D17D

Q44407642-1D74ADCE-FA2E-4B05-8775-510D2CAD1C18

Q44407642-1FD01FA4-1488-4C0B-BE22-B97CEC3C1962

Q44407642-2A6654E2-CD1D-422C-A471-EC83F4480EB0

Q44407642-727FB9B9-AEA2-40B8-998E-DFDD123CC02E

Q44407642-746161B0-B1BF-473A-AE2F-BCEA8B3E6799

Q44407642-83FEA50F-01F7-4A10-8F3A-A70AD6C6C3A5

Q44407642-84EC4964-D46D-4F16-B79B-68F6DEC75B98

P304

Q44407642-C45721EF-6BFC-4C5D-8C30-8EB5CB83B1CF

P31

Q44407642-6D0ED28B-0F2E-47D0-8345-884F5B574A69

P356

Q44407642-0303AD94-23DB-48D8-BA64-1CE8CE456CA8

P407

Q44407642-05FBF275-A6D3-46DA-905C-84C5B637AC36

P433

Q44407642-8107B1D2-694F-4E8D-931B-DBC13E2F7E7F

P478

Q44407642-A3B64AD4-0B6B-4B55-BD9F-5E6C74592713

P577

Q44407642-7F4579A0-2BED-47F1-B578-3291334DDD9D

P5875

Q44407642-A2D33415-BF9B-47BF-8480-A3DFCB0DFFB0

P698

Q44407642-89FC64BA-2157-47DD-B605-B0F0218514EA

P356

J.1600-6143.2007.02133.X

P1433

American Journal of Transplantation

P1476

Improvement in long-term renal ...... f a randomized clinical trial.

@en

P2093

F Rohde

http://www.w3.org/2001/XMLSchema#string

J Radermacher

http://www.w3.org/2001/XMLSchema#string

L Fricke

http://www.w3.org/2001/XMLSchema#string

M Burg

http://www.w3.org/2001/XMLSchema#string

T Wollbrink

http://www.w3.org/2001/XMLSchema#string

V Kliem

http://www.w3.org/2001/XMLSchema#string

P2860

Discovery of biomarkers in human urine and cerebrospinal fluid by capillary electrophoresis coupled to mass spectrometry: towards new diagnostic and therapeutic approaches.

Prophylaxis for CMV should now replace pre-emptive therapy in solid organ transplantation.

Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation.

Messenger RNA for FOXP3 in the urine of renal-allograft recipients.

Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials.

Cytomegalovirus infection in solid organ transplant recipients: new challenges and their implications for preventive strategies.

Benefits of cytomegalovirus prophylaxis in solid organ transplantation.

Cytomegalovirus in transplantation - challenging the status quo.

Clinical course of cytomegalovirus (CMV) viremia with and without ganciclovir treatment in CMV-seropositive kidney transplant recipients. Longitudinal follow-up of CMV pp65 antigenemia assay.

High variability between results of different in-house tests for cytomegalovirus (CMV) monitoring and a standardized quantitative plasma CMV PCR assay.

P304

975-983

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1600-6143.2007.02133.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2008-02-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5591397

http://www.w3.org/2001/XMLSchema#string

P698

18261177

http://www.w3.org/2001/XMLSchema#string